Medicines affordability in the US
Some people with diabetes in the US are increasingly finding it hard
to pay for their healthcare, especially those uninsured and in
high-deductible healthcare plans. This is not acceptable.
In line with our social responsibility, we have three offerings
today for people with diabetes who are struggling to afford their
- Our low-cost human insulin, which has been sold at Walmart for around $25 per vial for
almost two decades, and has recently been made available in other
national pharmacy chains through programmes with CVS and ESI. Around
500,000 Americans are using our human insulin through these
- Our co-pay cards to help defray patient
- Our patient assistance programme, which in 2018
provided free insulin to nearly 50,000 people with diabetes. Through
the programme, an individual with an annual income up to 49,960 US
dollars, and a family of four with a combined annual income up to
103,000 US dollars, may qualify for free Novo Nordisk medicines -
including all of our insulin products.
From 2 January 2020, we will add two new offerings to help address
insulin affordability for people living with diabetes in the US:
- Our $99 Cash Card Program offers people with diabetes up to
three vials or two packs of pens of any combination of Novo Nordisk
analog insulins for a flat cost of $99.00. While insulin usage
varies, this offering should cover most patients’ monthly insulin
- Our follow-on brand (authorised generic)
versions of two of our insulins -including our most prescribed
insulin – will be available at a 50 per cent discount compared to
the current list price of the branded versions.
Read more about our new insulin affordability initiatives.
The complexity of the US healthcare system means that arriving
at solutions that ensure affordable access to medicines for all is not
straightforward. However, we believe that with collaboration across
all parties in the system, sustainable solutions can be achieved.
We want to be part of a solution and we are actively working with
all parties in the US healthcare system to find ways that reduce the
burden on patients both in the short-term and for longer-term reform.